Epigenetic Modifiers Take Center Stage, Big Pharma Takes Notice
Executive Summary
Epigenetic modifiers are targeting a widening range of indications as growing knowledge of the underlying biology enables improved agents and therapeutic strategies. Nonetheless, issues of selectivity, toxicity, and finding adequate biomarkers still prevent the field from reaching its full potential.
You may also be interested in...
Servier Breaks Up With Pharmacyclics, Leaving Future Uncertain
Pharmacyclics and Servier decided to just be friends, leaving the biotech on the hook for the development of the mid-stage HDAC inhibitor abexinostat.
Rodin Therapeutics Inc.
Epigenetics continues to be a hot experimental field, but few drugs for modifying gene transcription to control cell-cycle progression have been tried out for central nervous system disorders despite scientific evidence linking aberrant epigenetic processes to several neurodegenerative conditions. Rodin Therapeutics Inc. is stepping in by bringing together international expertise in structural biology with CNS drug development leadership to discover and develop epigenetic agents for Alzheimer’s disease and other CNS disorders.
Novartis Previews Panobinostat PFS Advantage In Myeloma
Positive Phase III findings support Novartis’ plan for filing the pan-DAC inhibitor in 2014. The firm’s initial BLA for the compound, seeking accelerated approval in Hodgkin’s lymphoma, was rejected by FDA in 2011.